Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma
- 31 January 2009
- journal article
- case report
- Published by Elsevier BV in Bone
- Vol. 44 (1), 173-175
- https://doi.org/10.1016/j.bone.2008.08.132
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral ResearchJournal of Bone and Mineral Research, 2007
- Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?Bone, 2007
- Correlation Between Platelet-derived Growth Factor B Chain and Bone Resorption in Rat Periapical LesionsJournal of Endodontics, 2007
- Molecular Mechanisms of Action of Bisphosphonates: Current StatusClinical Cancer Research, 2006
- Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatmentThe Lancet Oncology, 2006
- Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With CancerJournal of Oncology Practice, 2006
- Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and TreatmentJournal of Oral and Maxillofacial Surgery, 2005
- Vascular endothelial growth factor receptors in osteoclast differentiation and functionBiochemical and Biophysical Research Communications, 2005
- Role of Tyrosine Kinase Inhibitors in Cancer TherapyThe Journal of pharmacology and experimental therapeutics, 2005
- Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic AcidThe Journal of pharmacology and experimental therapeutics, 2002